GlycoMimetics, Inc.

NasdaqCM:GLYC Stock Report

Market Cap: US$16.6m

GlycoMimetics Management

Management criteria checks 2/4

GlycoMimetics' CEO is Harout Semerjian, appointed in Aug 2021, has a tenure of 3.42 years. total yearly compensation is $2.39M, comprised of 26.7% salary and 73.3% bonuses, including company stock and options. directly owns 0.039% of the company’s shares, worth $6.43K. The average tenure of the management team and the board of directors is 3.4 years and 8.3 years respectively.

Key information

Harout Semerjian

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage26.7%
CEO tenure3.4yrs
CEO ownership0.04%
Management average tenure3.4yrs
Board average tenure8.3yrs

Recent management updates

Recent updates

We're A Little Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate

Jun 27
We're A Little Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate

GlycoMimetics Can Become A Game Changer In Blood Cancers

Mar 21

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

Mar 20
Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real

Jan 30

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

Nov 19
Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?

Jan 30
Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?

Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely

Oct 06
Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely

GlycoMimetics has a new Chief Medical Officer

Sep 06

GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K

Aug 03

GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely

Jun 04
GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely

GlycoMimetics Positive Data For AML Therapy Increasingly Likely

Mar 16

Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Nov 20
Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully

Aug 20
We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully

GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study

May 26

Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

May 12
Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

GlycoMimetics EPS beats by $0.04

May 03

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Mar 26
Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares

Feb 19
GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares

GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings

Jan 24
GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings

How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?

Dec 28
How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?

New data from GlycoMimetics highlights the efficacy Rivipansel in vaso-occlusive crisis in sickle cell disease

Dec 07

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Dec 07
Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

CEO Compensation Analysis

How has Harout Semerjian's remuneration changed compared to GlycoMimetics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$40m

Jun 30 2024n/an/a

-US$39m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023US$2mUS$638k

-US$37m

Sep 30 2023n/an/a

-US$38m

Jun 30 2023n/an/a

-US$37m

Mar 31 2023n/an/a

-US$42m

Dec 31 2022US$1mUS$614k

-US$47m

Sep 30 2022n/an/a

-US$54m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$64m

Dec 31 2021US$3mUS$244k

-US$63m

Compensation vs Market: Harout's total compensation ($USD2.39M) is above average for companies of similar size in the US market ($USD643.82K).

Compensation vs Earnings: Harout's compensation has increased whilst the company is unprofitable.

CEO

Harout Semerjian (54 yo)

3.4yrs

Tenure

US$2,389,418

Compensation

Mr. Harout Semerjian serves as Chief Executive Officer, President & Director of GlycoMimetics, Inc., since August 6, 2021. He served as President and Chief Executive Officer of Immunomedics Inc. since Apri...

Leadership Team

NamePositionTenureCompensationOwnership
Harout Semerjian
CEO, President & Director3.4yrsUS$2.39m0.039%
$ 6.4k
Rachel King
Co-Founder & Director22yrsUS$96.00k0.98%
$ 163.2k
Stephanie Irish
Vice President of Accounting6yrsno datano data
Christian Dinneen-Long
General Counsel & Company Secretary5.8yrsno datano data
Bruce Johnson
Senior VP & Chief Commercial Officer2.9yrsno data0.22%
$ 35.7k
Chinmaya Rath
Senior VP & Chief Business Officer1.9yrsno datano data
Shantha Tyavanagimatt
Senior Vice President of Technical Operationsless than a yearno datano data

3.4yrs

Average Tenure

54yo

Average Age

Experienced Management: GLYC's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Harout Semerjian
CEO, President & Director3.4yrsUS$2.39m0.039%
$ 6.4k
Rachel King
Co-Founder & Director22yrsUS$96.00k0.98%
$ 163.2k
Daniel Junius
Independent Director8.8yrsUS$118.50k0.15%
$ 25.3k
Timothy Pearson
Independent Chairman of the Board10.8yrsUS$138.00k0.038%
$ 6.3k
Scott Koenig
Independent Director7.8yrsUS$100.50k0.057%
$ 9.4k
Scott Jackson
Independent Director6.2yrsUS$111.00k0.0081%
$ 1.3k
Patricia S. Andrews
Independent Director7.6yrsUS$105.00k0.091%
$ 15.1k
Mark A. Goldberg
Independent Director10.5yrsUS$111.00kno data

8.3yrs

Average Tenure

65yo

Average Age

Experienced Board: GLYC's board of directors are considered experienced (8.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 16:05
End of Day Share Price 2025/01/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GlycoMimetics, Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ying HuangBarclays
John NewmanCanaccord Genuity
Naureen QuibriaCapital One Securities, Inc.